Literature DB >> 22393889

Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions.

Dmitriy Zamarin1, Peter Palese.   

Abstract

Newcastle disease virus (NDV) is an avian paramyxovirus, which has been demonstrated to possess significant oncolytic activity against mammalian cancers. This review summarizes the research leading to the elucidation of the mechanisms of NDV-mediated oncolysis, as well as the development of novel oncolytic agents through the use of genetic engineering. Clinical trials utilizing NDV strains and NDV-based autologous tumor cell vaccines will expand our knowledge of these novel anticancer strategies and will ultimately result in the successful use of the virus in the clinical setting.

Entities:  

Mesh：

Year:  2012        PMID： 22393889      PMCID： PMC4241685          DOI： 10.2217/fmb.12.4

Source DB:  PubMed          Journal:  Future Microbiol        ISSN： 1746-0913            Impact factor:   3.165


  180 in total

1.  Use of Newcastle disease virus vaccine (MTH-68/H) in a patient with high-grade glioblastoma.

Authors:  L K Csatary; T Bakács
Journal:  JAMA       Date:  1999-05-05       Impact factor: 56.272

2.  Newcastle disease virus activates macrophages for anti-tumor activity.

Authors:  V Schirrmacher; L Bai; V Umansky; L Yu; Y Xing; Z Qian
Journal:  Int J Oncol       Date:  2000-02       Impact factor: 5.650

3.  Newcastle disease virus infection induces B7-1/B7-2-independent T-cell costimulatory activity in human melanoma cells.

Authors:  C C Termeer; V Schirrmacher; E B Bröcker; J C Becker
Journal:  Cancer Gene Ther       Date:  2000-02       Impact factor: 5.987

4.  Generation of a recombinant chimeric Newcastle disease virus vaccine that allows serological differentiation between vaccinated and infected animals.

Authors:  B P Peeters; O S de Leeuw; I Verstegen; G Koch; A L Gielkens
Journal:  Vaccine       Date:  2001-02-08       Impact factor: 3.641

5.  Beneficial treatment of patients with advanced cancer using a Newcastle disease virus vaccine (MTH-68/H).

Authors:  L K Csatary; R W Moss; J Beuth; B Töröcsik; J Szeberenyi; T Bakacs
Journal:  Anticancer Res       Date:  1999 Jan-Feb       Impact factor: 2.480

6.  Selective transduction of protease-rich tumors by matrix-metalloproteinase-targeted retroviral vectors.

Authors:  K W Peng; R Vile; F L Cosset; S Russell
Journal:  Gene Ther       Date:  1999-09       Impact factor: 5.250

7.  Rescue of Newcastle disease virus from cloned cDNA: evidence that cleavability of the fusion protein is a major determinant for virulence.

Authors:  B P Peeters; O S de Leeuw; G Koch; A L Gielkens
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

8.  Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus.

Authors:  V Schirrmacher; C Haas; R Bonifer; T Ahlert; R Gerhards; C Ertel
Journal:  Gene Ther       Date:  1999-01       Impact factor: 5.250

9.  Active specific immunotherapy of renal cell carcinoma: cellular and humoral immune responses.

Authors:  U Zorn; S Duensing; F Langkopf; G Anastassiou; H Kirchner; M Hadam; J Knüver-Hopf; J Atzpodien
Journal:  Cancer Biother Radiopharm       Date:  1997-06       Impact factor: 3.099

10.  A recombinant newcastle disease virus with low-level V protein expression is immunogenic and lacks pathogenicity for chicken embryos.

Authors:  T Mebatsion; S Verstegen; L T De Vaan; A Römer-Oberdörfer; C C Schrier
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103
View more
  69 in total

1.  Antineoplastic activity of Newcastle disease virus strain D90 in oral squamous cell carcinoma.

Authors:  Chun-Xiao Zhang; Long-Wei Ye; Ying Liu; Xiao-Ya Xu; Dan-Rui Li; Yan-Qing Yang; Lu-Lu Sun; Jie Yuan
Journal:  Tumour Biol       Date:  2015-04-16

2.  Solution Structure, Self-Assembly, and Membrane Interactions of the Matrix Protein from Newcastle Disease Virus at Neutral and Acidic pH.

Authors:  E V Shtykova; M V Petoukhov; L A Dadinova; N V Fedorova; V Yu Tashkin; T A Timofeeva; A L Ksenofontov; N A Loshkarev; L A Baratova; C M Jeffries; D I Svergun; O V Batishchev
Journal:  J Virol       Date:  2019-03-05       Impact factor: 5.103

3.  Site-specific glycosylation of the Newcastle disease virus haemagglutinin-neuraminidase.

Authors:  Cassandra L Pegg; Christine Hoogland; Jeffrey J Gorman
Journal:  Glycoconj J       Date:  2016-12-07       Impact factor: 2.916

4.  Intravenously injected Newcastle disease virus in non-human primates is safe to use for oncolytic virotherapy.

Authors:  P R A Buijs; G van Amerongen; S van Nieuwkoop; T M Bestebroer; P R W A van Run; T Kuiken; R A M Fouchier; C H J van Eijck; B G van den Hoogen
Journal:  Cancer Gene Ther       Date:  2014-09-26       Impact factor: 5.987

5.  Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.

Authors:  Gayathri Vijayakumar; Stephen McCroskery; Peter Palese
Journal:  J Virol       Date:  2020-01-17       Impact factor: 5.103

6.  Design and Production of Newcastle Disease Virus for Intratumoral Immunomodulation.

Authors:  Gayathri Vijayakumar; Dmitriy Zamarin
Journal:  Methods Mol Biol       Date:  2020

7.  Antitumor and immunostimulatory activities of a genotype V recombinant attenuated veterinary Newcastle disease virus vaccine.

Authors:  Oscar Antonio Ortega-Rivera; J Luis Quintanar; Susana Del Toro-Arreola; Ángel G Alpuche-Solis; Mayra J Esparza-Araiza; Eva Salinas
Journal:  Oncol Lett       Date:  2017-11-09       Impact factor: 2.967

8.  Transplanted tumor growth and the incidence of T-lymphocyte populations in the spleen of newcastle virus-treated mice.

Authors:  Ana Jurin Martić; Siniša Ivanković; Mariastefania Antica; Nevenka Hiršl; Tomislav Jukić; Mislav Jurin
Journal:  Cancer Biother Radiopharm       Date:  2015-03-12       Impact factor: 3.099

9.  Enhancement of the proapoptotic properties of newcastle disease virus promotes tumor remission in syngeneic murine cancer models.

Authors:  Sara Cuadrado-Castano; Juan Ayllon; Mena Mansour; Janis de la Iglesia-Vicente; Stefan Jordan; Shashank Tripathi; Adolfo García-Sastre; Enrique Villar
Journal:  Mol Cancer Ther       Date:  2015-03-11       Impact factor: 6.261

10.  Current status of gene therapy for brain tumors.

Authors:  Andrea M Murphy; Samuel D Rabkin
Journal:  Transl Res       Date:  2012-12-11       Impact factor: 7.012
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.